Gas Sensors Expand SSB’s PAT Portfolio

Source: PharmaManufacturing.com

Jul 16, 2013

Sartorius Stedim Biotech

Sartorius Stedim Biotech has entered into a global sales partnership with BlueSens, the German experts in gasometric engineering. BlueSens is a specialized provider of sensor technology, which is used by the biopharmaceutical industry for inline measurement of gases in microbial fermentation and cell cultivation processes. The cooperation agreement between SSB and BlueSens provides that, alongside BlueSens, SSB will assume global marketing and distribution of its partner company’s oxygen and carbon dioxide sensors, and sell these as private label products under SSB’s brand name BioPATXgas.
                                                    
"These sensors make our bioreactors even more intelligent," says Stefan Schlack, senior vice president of marketing at SSB. "They analyze metabolic processes in real time during cultivation and help our customers better understand their processes. Used in combination with our software, these sensors are powerful tools for optimizing biopharmaceutical production processes and acceleratingdevelopment."
 
Dr. Holger Müller, BlueSens sales and marketing manager, said, “In fermentation, Sartorius Stedim Biotech is among the leading suppliers worldwide and has a strong, global sales network. We would like to leverage these advantages in order to reach considerably more customers. I am looking forward to our partnership.”
 
BioPATXgas will be sold as an equipment package that includes SSB’s single-use and reusable bioreactors. Ready to use right out of the box, the sensors are completely integrated into SSB’s BioPAT DCU control units and SCADA software, called BioPATMFCS.
 
In conjunction with Sartorius software, BioPATXgas analyzes critical process variables, such as oxygen uptake rate (OUR), carbon dioxide production rate (CPR) or respiratory quotient (RQ).
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments